IndiaBioscience’s Post

A collaborative study led by Sudipta Maiti, @TIFR, sheds light on the deadly partnership between ApoE (Apolipoprotein E) and Aβ (amyloid-beta) — two major protein players in Alzheimer’s disease. 🧠 💡 Their innovative FLIM (fluorescence lifetime microscopy) imaging approach offers potential value for drug development, promising better disease prediction and treatment strategies, and holding implications for neurological health and therapeutics.🔬 ✍️ Rohini Subrahmanyam https://buff.ly/3wbqVlI

#ICYMI In a recent Drug Development & Delivery article, our Distinguished Scientist and Strategic Leader, Art Levin, PhD, explores our efforts to develop a new class of RNA therapeutics called AOCs. A rapidly growing body of evidence reinforces the significant promise of AOCs to address many areas of unmet need in health in entirely new ways, starting with skeletal muscle diseases. At Avidity, we're harnessing our proprietary AOC platform to advance clinical programs targeting three rare muscle disorders: myotonic dystrophy type 1 (#DM1), Duchenne muscular dystrophy (#DMD), and facioscapulohumeral muscular dystrophy (#FSHD). Our early results with AOC technology highlight its ability to target diverse rare muscle disorders, positioning us as leaders in this cutting-edge field of innovation. Read the full article and learn about our recent milestones in all three programs: https://lnkd.in/eq-MCCVf

MHC molecules are pivotal in regulating immune responses by presenting antigenic peptides from self and foreign proteins. 🧬 We've refined an automated workflow for MHC-associated peptide enrichment and mass spectrometry (MS)-based #proteomics analysis, ensuring scalability and reproducibility for HLA class I and II immunopeptidome. Our new method exhibits high reproducibility in ramping experiments from 2.5 mg tissue or 5 million PBMCs. 💡Explore our recent #AACR2024 poster to delve deeper into how our #TrueDiscovery® Immunopeptidome Profiling service facilitates immunopeptide analysis with minimal sample input: https://lnkd.in/ez7MmJam Contact us to leverage these readily available proteome data insights in your drug discovery and development research: biognosys.com/contact

Today we announce a collaboration with University of California, San Francisco towards finding better genetic switches for the use in regulatory T (Treg) #celltherapy. Tregs are an important type of immune cells that can prevent rejection during organ transplantation and reduce the symtoms of autoimmune disease. The Qizhi Tang lab has previously shown Tregs can, for example, reverse type 1 diabetes. While biotech and pharma are crucial bringing innovations to the market, academic research remains the foundation for groundbreaking R&D. Therefore, I am excited that we can join leverage the expertise of the Tang and Shy lab with Annogen's promoter discovery platform. Brian Shy Joris van Arensbergen

Glucose transporter 1 (GLUT1) overexpression has been in the news by Crystal Mackall (https://lnkd.in/eFFb74Wp) and Michel Sadelain (https://lnkd.in/eZ4fN9ya). This has shown to increase #potency and #persistence by altering the cells metabolic pathways. Did you know that a simple method to increase GLUT1 expression for #cellandgenetherapy is altering the cell culture environment (mimicking #TME)? It also increases their persistent tumor killing capacity (https://lnkd.in/esAiqeV4). xcellbio bioreactor and Cytek Biosciences spectral FC analysis.

Several factors contribute to the development and progression of #Alzheimer's disease. It is increasingly evident that a multi-targeted approach is needed to slow and reverse the destruction caused by this complex disease. While amyloid-beta buildup and tau tangles have been the focus of research and drug development, attention has been turning to other pathological factors affecting disease progression, including neuroprotection and synaptic dysfunction. InMed's INM-901 is a novel drug candidate that may target several biological pathways associated with #Alzheimers disease. Preclinical studies of INM-901 demonstrate neuroprotective effects, reduced neuroinflammation and an ability to promote the growth of neurites. More about INM-901: https://ow.ly/ozUo50SNJo7 $INM

Transform your drug discovery with our Covalent Fragments Pre-Plated Library! https://buff.ly/3X20vgL This curated collection of 1,400 compounds is designed to target proteins through covalent bonding—perfect for advancing research in arthritis, infections, and cancer. Backed by the latest research, these compounds, including acrylamides and sulfonyl fluorides, are pre-plated and ready to use. Stock available now—order today to advance your projects!🔍 For all the details, contact us at sales(AT)chem-space.com #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

We look forward to presenting preclinical research for our tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution. The findings presented in two posters demonstrate that ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis. The posters will be available on the aTyr website once presented. For more information, read here: https://bit.ly/41jQwpI

🚀 Exciting news from Jillion Therapeutics! They have been awarded $496,373 by the U.S. Department of Health and Human Services (HHS)  , specifically the National Institutes of Health and the NIH National Institute on Aging. This funding will support their groundbreaking research on targeting biologically relevant tau monomers and oligomers using a novel DNA-encoded library (DEL) drug discovery platform to treat Alzheimer's disease and tauopathies. #SBIR #STTR #Innovation 🔬 This Phase I SBIR project aims to identify small molecular weight compounds that can bind to tau protein and modify its biology, ultimately reducing its toxicity. The research will focus on overcoming current limitations in tau drug discovery by using a DEL screening approach, which allows for high-throughput screening with minimal protein usage. The project will last for 12 months, starting on September 1, 2024, and ending on August 31, 2025. #Healthcare #Research #Alzheimers

This comprehensive review focuses on the bioactive flavonoid #baicalein, extracted from Scutellaria baicalensis and Oroxylum indicum roots, extensively analyzing its pharmacological effects through in vitro and in vivo studies. Baicalein demonstrates diverse benefits, such as #anti-cancer, #antidiabetic, #antimicrobial, and #neuroprotective properties. The review emphasizes its potential as a complementary medicine, advocating for further clinical studies to validate its effectiveness and safety. | https://ow.ly/mRUL50Sf9iP